uniQure NV

QURE48

$5.65arrow_drop_down1.90%-$0.11

QURE48

$5.65

arrow_drop_down1.90%-$0.11

Performance History

Key Stats
Open	$5.91
Prev. Close	$5.76
EPS	-5.92
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	5.67	5.91
52 Week Range	3.73	11.35

Ratios







EPS	-5.92

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About uniQure NV (QURE)

uniQure NV (QURE) is a leading gene therapy company that focuses on developing and commercializing transformative therapies for patients with severe genetic diseases. The company is headquartered in Amsterdam, the Netherlands, and has a strong global presence. uniQure's mission is to bring innovative gene therapies to patients, providing them with potential cures for their diseases. With a strong pipeline and a commitment to scientific excellence, uniQure is a pioneer in the field of gene therapy.

uniQure's stock price history shows a promising upward trend. Over the past year, the stock has experienced significant growth, with a 52-week range of $30.45 to $60.80. The stock has shown resilience in the face of market volatility and has consistently outperformed the industry. This solid performance is a testament to the strength of uniQure's business model and its ability to deliver value to shareholders.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Matthew Craig Kapusta
Headquarters: Amsterdam
Employees: 501
Exchange: NASDAQ

Keep an eye on uniQure NV

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is uniQure NV's (QURE) price per share?

The current price per share for uniQure NV (QURE) is $5.65. The stock has seen a price change of -$0.11 recently, indicating a -1.91% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for uniQure NV (QURE)?

For uniQure NV (QURE), the 52-week high is $11.35, which is 100.88% from the current price. The 52-week low is $3.73, the current price is 51.47% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is uniQure NV (QURE) a growth stock?

uniQure NV (QURE) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying uniQure NV as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is uniQure NV (QURE) stock price performance year to date (YTD)?

As of the latest data, uniQure NV (QURE) has a year-to-date price change of -18.47%. Over the past month, the stock has experienced a price change of -14%. Over the last three months, the change has been 23.63%. Over the past six months, the figure is 13.68%. Looking at a longer horizon, the five-year price change stands at -87.69%.

help

Is uniQure NV (QURE) a profitable company?

uniQure NV (QURE) has a net income of -$308.48M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 13.98% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -425.99% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $15.84M, although specific revenue growth data is currently not available. The gross profit is $2.22M. Operating income is noted at -$282.87M. Furthermore, the EBITDA is -$217.12M.

help

What is the market capitalization of uniQure NV (QURE)?

uniQure NV (QURE) has a market capitalization of $280.5M. The average daily trading volume is 409.9K, indicating the stock's liquidity and investor engagement.

News

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology